Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1401 - 1422 of 1422

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 600 of 600

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1526 - 1550 of 2132

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
brodalumab	TS0001-PsO-Updated-Streamlined-Rec.pdf SR0547_cdr_complete_Siliq_June_22_18.pdf SR0547_Siliq_CL_Report.pdf SR0547_Siliq_PE_Report.pdf SR0547_Brodalumab_PI_Submissions.pdf	Jul 16, 2018	Reimbursement Review		Complete	SR0547-000
dupilumab	SR0533_cdr_complete_Dupixent_July_9_2018.pdf SR0533_Dupixent_CL_Report.pdf SR0533_Dupixent_PE_Report.pdf SR0533_Duxipent_Patient_Submsissions.pdf	Jul 10, 2018	Reimbursement Review		Complete	SR0533-000
letermovir	SR0545_cdr_complete_Prevymis_June_22_2018.pdf SR0545_Prevymis_CL_Report.pdf SR0545_Prevymis_PE_Report.pdf SR0545_Prevymis_PI_Submissions.pdf	Jul 9, 2018	Reimbursement Review		Complete	SR0545-000
Tecentriq for Non-Small Cell Lung Cancer – Details	pcodr_profund_10115_atezolizumab_tecentriq_nsclc.pdf pcodr_atezolizumab_tecentriq_nsclc_fn_rec.pdf pcodr_atezolizumab_tecentriq_nsclc_fn_cgr.pdf pcodr_atezolizumab_tecentriq_nsclc_fn_egr.pdf pcodr_atezolizumab_tecentriq_nsclc_in_rec.pdf pcodr_atezolizumab_tecentriq_nsclc_pagfdk.pdf pcodr_atezolizumab_tecentriq_nsclc_fdk_hlroche.pdf pcodr_atezolizumab_tecentriq_nsclc_clnfdk.pdf pcodr_atezolizumab_tecentriq_nsclc_coi_pt.pdf pcodr_atezolizumab_tecentriq_nsclc_coi_cln.pdf	Jul 6, 2018	Reimbursement Review		Complete	PC0115-000
Drugs for Rare Diseases: A Review of National and International Health Technology Assessment Agencies and Public Payers’ Decision-Making Processes		Jun 26, 2018	Health Technology Review	Environmental Scan	Completed	ES0326-000
netupitant / palonosetron	SR0548_cdr_complete_Akynzeo_June_22_18.pdf SR0548_Akynzeo_CL_Report.pdf SR0548_Akynzeo_PE_Report.pdf	Jun 22, 2018	Reimbursement Review		Complete	SR0548-000
Dolutegravir / rilpivirine	SR0551_cdr_complete_Juluca_June_22_18.pdf SR0551_Juluca_CL_Report.pdf SR0551_Juluca_PE_Report.pdf SR0551_Juluca_PI_Submissions.pdf	Jun 22, 2018	Reimbursement Review		Complete	SR0551-000
Recommendations Framework for Drugs for Rare Diseases: A Review of National and International Health Technology Assessment Agencies and Public Payers’ Decision-Making Processes		Jun 22, 2018	Health Technology Review			ES0326-000
Tiotropium bromide	SR0412 Spiriva Respimat.pdf SR0412-complete-Spiriva-Respimat-July-20-15-e.pdf SR0412_SpirivaRespimat_CL_Report.pdf SR0412_SpirivaRespimat_PE_Report.pdf SR0412_SpirivaRespimat_PI_Submissions.pdf	May 23, 2018	Reimbursement Review		Complete	SR0412-000
ledipasvir, sofosbuvir	SF0465 Harvoni.pdf SF0465_complete_Harvoni RFA_May_19-16.pdf SF0465_Harvoni_Hep_C_RfA_PI_Submissions.pdf SF0465_Harvoni_RfA_Review_Report.pdf	May 23, 2018	Reimbursement Review		Complete	SF0465-000
Opdivo for classical Hodgkin Lymphoma (after failure of ASCT) – Details	pcodr_profund_nivolumab_opdivo_chl_fail_asct.pdf pcodr_nivolumab_opdivo_cHL_fn_rec.pdf pcodr_nivolumab_opdivo_cHL_fn_egr.pdf pcodr_nivolumab_opdivo_cHL_fn_cgr.pdf pcodr_nivolumab_opdivo_chl_in_rec.pdf pcodr_nivolumab_opdivo_cHL_pagfdk.pdf pcodr_nivolumab_opdivo_cHL_ptfdk.pdf pcodr_nivolumab_opdivo_cHL_clnfdk.pdf pcodr_nivolumab_opdivo_cHL_fdk_bms.pdf pcodr_nivolumab_opdivo_cHL_coi_pt.pdf pcodr_nivolumab_opdivo_cHL_coi_cln.pdf	May 22, 2018	Reimbursement Review		Complete	PC0120-000
latanoprost	SR0541_cdr_complete_Monoprost_apr-26-18_e.pdf SR0541_Monoprost_CL_Report.pdf SR0541_Monoprost_PE_Report.pdf	May 17, 2018	Reimbursement Review		Complete	SR0541-000
ocrelizumab	SR0542_cdr_complete_Ocrevus_PPMS_Apr_30_18_e.pdf SR0542_Ocrevus_PPMS_CL_Report.pdf SR0542_Ocrevus_PPMS_PE_Report.pdf SR0542_Ocrevus_PPMS_PI_Submissions.pdf	May 10, 2018	Reimbursement Review		Complete	SR0542-000
Lartruvo for Advanced Soft Tissue Sarcoma – Details	pcodr_profund_olaratumab_lartruvo_sts.pdf pcodr_olaratumab_lartruvo_sts_fn_rec.pdf pcodr_olaratumab_lartruvo_sts_fn_cgr.pdf pcodr_olaratumab_lartruvo_sts_fn_egr.pdf pcodr_olaratumab_lartruvo_sts_in_rec.pdf pcodr_olaratumab_lartruvo_sts_pagfdk.pdf pcodr_olaratumab_lartruvo_sts_fdk_elc.pdf pcodr_olaratumab_lartruvo_sts_clnfdk.pdf pcodr_olaratumab_lartruvo_sts_coi_pt.pdf pcodr_olaratumab_lartruvo_sts_coi_cln.pdf	May 3, 2018	Reimbursement Review		Complete	PC0111-000
Stivarga for Unresectable Hepatocellular Carcinoma (HCC) – Details	pcodr_provfund_10119_regorafenib_stivarga_unresectable_hcc.pdf pcodr_regorafenib_stivarga_hcc_fn_rec.pdf pcodr_regorafenib_stivarga_hcc_fn_cgr.pdf pcodr_regorafenib_stivarga_hcc_fn_egr.pdf pcodr_regorafenib_stivarga_hcc_in_rec.pdf pcodr_regorafenib_stivarga_hcc_pagfdk.pdf pcodr_regorafenib_stivarga_hcc_fdk_bayer.pdf pcodr_regorafenib_stivarga_hcc_ptfdk.pdf pcodr_regorafenib_stivarga_hcc_clnfdk.pdf pcodr_regorafenib_stivarga_hcc_coi_pt.pdf pcodr_regorafenib_stivarga_hcc_coi_cln.pdf	May 3, 2018	Reimbursement Review		Complete	PC0119-000
Kisqali for Metastatic Breast Cancer – Details	pcodr_provfund_10112_ribocliclib_kisqali_mbc.pdf pcodr_ribociclib_kisqali_mbc_fn_rec.pdf pcodr_ribociclib_kisqali_mbc_fn_cgr.pdf pcodr_ribociclib_kisqali_mbc_fn_egr.pdf pcodr_ribociclib_kisqali_mbc_in_rec.pdf pcodr_ribociclib_kisqali_mbc_pagfdk.pdf pcodr_ribociclib_kisqali_mbc_fdk_novartis.pdf pcodr_ribociclib_kisqali_mbc_ptfdk.pdf pcodr_ribociclib_kisqali_mbc_clnfdk.pdf pcodr_ribociclib_kisqali_mbc_coi_pt.pdf pcodr_ribociclib_kisqali_mbc_coi_cln.pdf	May 3, 2018	Reimbursement Review		Complete	PC0112-000
tenofovir alafenamide	SR0537_Vemlidy_complete_Mar-28-18.pdf SR0537_Vemlidy_CL_Report.pdf SR0537_Vemlidy_PE_Report.pdf SR0537_Vemlidy_PI_Submissions.pdf	Apr 30, 2018	Reimbursement Review		Complete	SR0537-000
tocilizumab	SR0534_Actemra_GCA_complete_Mar-27-18.pdf SR0534_ActemraGCA_CL_Report.pdf SR0534_Actemra_GCA_PE_Report.pdf SR0534_Actemra_GCA_PI_Submissions.pdf	Apr 30, 2018	Reimbursement Review		Complete	SR0534-000
Erbitux for Left Sided Metastatic Colorectal Cancer – Details		Apr 26, 2018	Reimbursement Review		Cancelled	PC0128-000
Drugs for the Management of Rheumatoid Arthritis		Apr 25, 2018	Health Technology Review	Health Technology Assessment	Completed	HT0010-000
Apomorphine	SR0527_Movapo_complete-Jan-25-18.pdf SR0527_Movapo_CL_Report.pdf SR0527_Movapo_PE_Report.pdf SR0527_Movapo_Patient_Input.pdf	Apr 18, 2018	Reimbursement Review		Complete	SR0527-000
Use of Real-World Evidence in Single-Drug Assessments Environmental Scan		Apr 18, 2018	Health Technology Review	Environmental Scan	Completed	ES0323-000
Vectibix for Left Sided Metastatic Colorectal Cancer – Details	pcodr_profund_panitumumab_vectibix_ls_mcrc.pdf pcodr_panitumumab_vectibix_ls_mcrc_fn_rec.pdf pcodr_panitumumab_vectibix_ls_mcrc_fn_cgr.pdf pcodr_panitumumab_vectibix_ls_mcrc_fn_egr .pdf pcodr_panitumumab_vectibix_ls_mcrc_in_rec.pdf pcodr_panitumumab_vectibix_ls_mcrc_pagfdk.pdf pcodr_panitumumab_vectibix_ls_mcrc_fdk_amgen.pdf pcodr_panitumumab_vectibix_ls_mcrc_ptfdk.pdf pcodr_panitumumab_vectibix_ls_mcrc_clnfdk.pdf pcodr_panitumumab_vectibix_ls_mcrc_coi_pt.pdf pcodr_panitumumab_vectibix_ls_mcrc_coi_cln.pdf	Apr 16, 2018	Reimbursement Review		Complete	PC0118-000
Alecensaro for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (second line) – Details	AlectinibAlecensaro_NSCLCsecondline10114ProvFunding.pdf pcodr_alectinib_alecensaro_nsclc_2ln_fn_rec.pdf pcodr_alectinib_alecensaro_nsclc_2ln_fn_cgr .pdf pcodr_alectinib_alecensaro_nsclc_2ln_fn_egr.pdf pcodr_alectinib_alecensaro_nsclc_2ln_in_rec.pdf pcodr_alectinib_alecensaro_nsclc_2ln_pagfdk.pdf pcodr_alectinib_alecensaro_nsclc_2ln_fdk_roche.pdf pcodr_alectinib_alecensaro_nsclc_2ln_coi_pt.pdf pcodr_alectinib_alecensaro_nsclc_2ln_coi_cln.pdf	Apr 16, 2018	Reimbursement Review		Complete	PC0114-000
glecaprevir pibrentasvir	SR0523_Maviret_complete-Jan-25-18.pdf SR0523_Maviret_CL_Report.pdf SR0523_Maviret_PE_Report.pdf SR0523_Maviret_Patient_Input.pdf	Apr 12, 2018	Reimbursement Review		Complete	SR0523-000